HBeAg induces neutrophils activation impairing NK cells function in patients with chronic hepatitis B
- PMID: 38829576
- DOI: 10.1007/s12072-024-10689-z
HBeAg induces neutrophils activation impairing NK cells function in patients with chronic hepatitis B
Abstract
Background: The role of neutrophils in hepatitis B virus (HBV) infection has been a subject of debate due to their involvement in antiviral responses and immune regulation. This study aimed to elucidate the neutrophil characteristics in patients with chronic hepatitis B (CHB).
Methods: Through flow cytometry and ribonucleic acid-sequencing analysis, the phenotypes and counts of neutrophils were analyzed in patients with CHB. Moreover, the effects of HBeAg on neutrophils and the corresponding pattern recognition receptors were identified. Simultaneously, the cross-talk between neutrophils and natural killer (NK) cells was investigated.
Results: Neutrophils were activated in patients with CHB, characterized by higher expression levels of programmed death-ligand 1 (PD-L1), cluster of differentiation 86, and interleukin-8, and lower levels of CXC motif chemokine receptor (CXCR) 1 and CXCR2. Hepatitis B e antigen (HBeAg) partially induces neutrophil activation through the Toll-like receptor 2 (TLR2). A consistent upregulation of the TLR2 and HBeAg expression was observed in patients with CHB. Notably, the genes encoding molecules pivotal for NK-cell function upon NK receptor engagement enriched in neutrophils after HBeAg activation. The HBeAg-activated neutrophils demonstrated the ability to decrease the production of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) in NK cells, while the PD-1 and PD-L1 pathways partially mediated the immunosuppression.
Conclusions: The immunosuppression of neutrophils induced by HBeAg suggests a novel pathogenic mechanism contributing to immune tolerance in patients with CHB.
Keywords: Chronic hepatitis B; HBeAg; Immunosuppression; Innate immunity; Natural killer cells; Neutrophils; PD-L1; PRRs; RNA-seq; TLRs.
© 2024. Asian Pacific Association for the Study of the Liver.
Similar articles
-
Intrahepatic natural killer cell activation, but not function, is associated with HBsAg levels in patients with HBeAg-negative chronic hepatitis B.Liver Int. 2014 Mar;34(3):396-404. doi: 10.1111/liv.12272. Epub 2013 Jul 25. Liver Int. 2014. PMID: 23890390
-
Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients.J Viral Hepat. 2016 Mar;23(3):170-9. doi: 10.1111/jvh.12477. Epub 2015 Oct 5. J Viral Hepat. 2016. PMID: 26436722
-
Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein.Hepatology. 2007 Jan;45(1):102-10. doi: 10.1002/hep.21482. Hepatology. 2007. PMID: 17187404
-
Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function.Cell Mol Immunol. 2021 Feb;18(2):461-471. doi: 10.1038/s41423-020-00601-8. Epub 2021 Jan 11. Cell Mol Immunol. 2021. PMID: 33432062 Free PMC article.
-
Monocyte-derived Galectin-9 and PD-L1 differentially impair adaptive and innate immune response in chronic HBV infection and their expression remain unaltered after antiviral therapy.Front Immunol. 2024 Oct 9;15:1474853. doi: 10.3389/fimmu.2024.1474853. eCollection 2024. Front Immunol. 2024. PMID: 39445017 Free PMC article.
Cited by
-
IL-1b-Bearing NETs: Bridging Inflammation to Early Cirrhosis in Hepatitis B.Int J Mol Sci. 2025 Jun 15;26(12):5733. doi: 10.3390/ijms26125733. Int J Mol Sci. 2025. PMID: 40565198 Free PMC article.
-
Innate immune recognition in hepatitis B virus infection.Virulence. 2025 Dec;16(1):2492371. doi: 10.1080/21505594.2025.2492371. Epub 2025 Apr 20. Virulence. 2025. PMID: 40253712 Free PMC article. Review.
References
-
- Hutin Y, Nasrullah M, Easterbrook P, Nguimfack BD, Burrone E, Averhoff F, et al. Access to treatment for hepatitis B virus infection—worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(28):773–777. https://doi.org/10.15585/mmwr.mm6728a2 - DOI - PubMed - PMC
-
- Spyrou E, Smith CI, Ghany MG. Hepatitis b: current status of therapy and future therapies. Gastroenterol Clin North Am. 2020;49(2):215–238. https://doi.org/10.1016/j.gtc.2020.01.003 - DOI - PubMed - PMC
-
- Khanam A, Chua JV, Kottilil S. Immunopathology of chronic hepatitis b infection: role of innate and adaptive immune response in disease progression. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22115497 - DOI - PubMed - PMC
-
- Yang G, Wan P, Zhang Y, Tan Q, Qudus MS, Yue Z, et al. Innate immunity, inflammation, and intervention in HBV infection. Viruses. 2022. https://doi.org/10.3390/v14102275 - DOI - PubMed - PMC
-
- Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol. 2016;64(1 Suppl):S60–S70. https://doi.org/10.1016/j.jhep.2016.01.028 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials